UCB reports strong financial performance in 2010

UCB has published its financial statement for the 2010 fiscal year, expressing satisfaction with its growth during the period.

The pharmaceutical company saw rising demand for key products such as Cimzia, Vimpat and Neupro in the last 12 months, which helped to drive its annual revenue up by two percent year-on-year to 3.22 billion euros (2.77 billion pounds).

During the year, the firm was able to meet clinical milestones on time across all of its new developmental products, while improving its corporate efficiency and optimising its manufacturing network.

UCB also expressed confidence in its long-term growth prospects, due to the fact that after 2011 it does not expect to see any major patent expiries for more than a decade.

Roch Doliveux, chief executive officer of the company, said: "UCB has now entered the last part of its transformation into a patient-centric global biopharmaceutical leader with intense growth of our new products and a promising pipeline."

Earlier this month, UCB was presented with a Good Design Award for its prefilled Cimzia syringe offering and accompanying packaging.